Inhibition of EGFR using the tyrosine kinase inhibitors (TKIs) erlotinib or gefitinib could induce apoptosis of NSCLC with mutant constitutively active EGFR (ΔL747-S752 or L858R) through a process dependent on Bim [306, 307, 309]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.